44.50
-3.03%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pharmaron Beijing Co
Its shares trade on Shenzhen under the ticker 300759.SZ. It has been listed since 28 January 2019. In the fiscal year to 31 December 2025, it reported revenue of CN¥14.10bn and net income of CN¥1.66bn. At that date it held total assets of CN¥27.09bn and shareholders' equity of CN¥15.06bn.
Pharmaron Beijing Co Ltd is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Beijing, Beijing. The company went IPO on 2019-01-28. Pharmaron Beijing Co Ltd is a China-based company providing research and manufacturing service portfolio, medical tools and clinical research testing services in the process of discovering, developing and manufacturing small molecule drugs, cell therapy and gene therapy. The firm operates in four segments. Laboratory Services segment includes laboratory chemistry, drug metabolism and pharmacokinetics/absorption, distribution, metabolism and excretion, biology, safety assessment and discovery of biological agents. CMC Service segment is engaged in process development and preform production and analysis. Clinical Development Service segment includes clinical research, on-site management organization, regulatory biological analysis and radioactive labeling scientific services. The Biologics and CGT Services segment is engaged in the discovery, development and production of macromolecular drugs, development of cell gene therapy methods and other businesses.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 28 Jan 2019
- Employees
- 19,481
- Website
- pharmaron.cn ↗
Leadership
Pay as last reported
- Mr. Boliang LouExecutive Chairman of the Board, Chief Executive Officer, since 2016CN¥2.2m
- Mr. Xiaoqiang LouPresident, Chief Operating Officer, Executive Director, since 2016CN¥1.9m
- Mr. Shing Chung LiChief Financial Officer, Secretary of the BoardCN¥2.0m
- Ms. Bei ZhengExecutive Vice President, Executive Director, since 2016CN¥1.6m
- Dr. Hua YangChief Scientific OfficerCN¥1.9m
- Mr. Jiaqing LiNon-Executive Director
- Ms. Xuan WanNon-Executive Director
- Ms. Lihua LiIndependent Non-Executive DirectorCN¥300,000
- Mr. Kwan Hung TsangIndependent Non-Executive DirectorCN¥300,000
- Mr. Jian YuIndependent Non-Executive DirectorCN¥300,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 85
- Environment
- 99
- Social
- 83
- Governance
- 73
- Direct emissions (scope 1)
- 34,268 t
- Energy emissions (scope 2)
- 164,432.78 t
- Value chain emissions (scope 3)
- 414,817.33 t
- Women in the workforce
- 55.13804%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pharmaron Beijing employs 19,481 full-time employees in Beijing, China.
- Pharmaron Beijing offers comprehensive services in Life Sciences Tools & Services industry.
- Pharmaron Beijing provides research and manufacturing services for small molecule drugs and cell therapy.
Weaknesses
- Pharmaron Beijing's headquarters is in Beijing, China, which may limit global reach.
- Pharmaron Beijing's IPO was on 28 January 2019, a relatively recent listing.
- Pharmaron Beijing operates in four segments, which may require significant management focus.
Opportunities
- Pharmaron Beijing can expand its Biologics and CGT Services segment in China's growing health care market.
- Pharmaron Beijing can leverage its Laboratory Services segment for international partnerships.
- Pharmaron Beijing can grow its CMC Service segment for small molecule drug development.
Threats
- Pharmaron Beijing faces competition from other Life Sciences Tools & Services companies in China.
- Pharmaron Beijing must navigate regulatory challenges in the Chinese health care sector.
- Pharmaron Beijing's reliance on the Chinese market exposes it to economic fluctuations in China.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.